12.03.2024 17:17:07
EQS-News: Results of the Annual General Meeting 2024 for the financial year 2022/23 of BRAIN Biotech AG
EQS-News: BRAIN Biotech AG
/ Key word(s): AGM/EGM
The establishment of silent partnerships between BRAIN Biotech AG and Hessen Kapital I GmbH and MBG H Mittelständische Beteiligungsgesellschaft Hessen mbH – for the financing of innovative research projects at the locations in Hesse – received approval rates of over 99% in each case. 65,99 % of the share capital was represented at the time of the voting. In his speech to shareholders, CEO The detailed voting results and all other documents relating to the Annual General Meeting are available on the BRAIN Biotech website at: https://www.brain-biotech.com/investors/financial-publications/2022-23 +++ BRAIN Biotech AG is a leading European supplier of biobased products and solutions such as enzymes and proteins, microbial production strains, natural compounds and biotechnological solutions for more sustainable industrial processes. The company focuses on the fields of nutrition, health and environment. BRAIN Biotech AG is the parent company of the international BRAIN Biotech Group. The Group’s business activities are divided into three segments: The BioProducts segment comprises the product business with specialty enzymes and other proteins, for which the Group operates fermentation facilities in the United Kingdom and production facilities in continental Europe and the United States. The BioScience segment offers research-intensive custom solutions based on enzyme technology, strain development, bioprocess development and natural product screening. The BioIncubator segment conducts its own R&D projects or those initiated with partners with high value-added potential. A particularly promising incubator project is the development of the Company’s own CRISPR-based gene editing technology platform, which is currently being established and expanded by Akribion Genomics (in foundation planning). Through its own R&D activities, BRAIN Biotech Group is continuously expanding its product portfolio in the field of specialty enzymes and small molecules. The latter are the starting point for screenings, e.g. for novel drug candidates for pharmaceutical applications. BRAIN Biotech AG has been listed on the Prime Standard of the Frankfurt Stock Exchange since February 9, 2016 (ticker symbol: BNN; securities identification number: ISIN DE0005203947 / WKN 520394). The company employs approximately 330 people and generated revenues of EUR 55.3 million in the fiscal year 2022/23. For more information, please visit: https://www.brain-biotech.com, LinkedIn, Threads and YouTube. Martina Schuster Dr. Stephanie Konle This press release contains forward-looking statements. These statements reflect the current views, expectations, and assumptions of the management of BRAIN Biotech AG, and are based on information currently available to the management. Forward-looking statements are no guarantees of future performance, and entail both known and unknown risks as well as uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. Numerous factors exist that could influence the future performance of and future developments at BRAIN Biotech AG and the BRAIN Biotech Group. Such factors include, but are not limited to, changes in the general economic and competitive environment, risks associated with capital markets, currency exchange rate fluctuations, changes in international and national laws and regulations, in particular with respect to tax laws and regulations, as well as other factors. BRAIN Biotech AG does not undertake any obligation to update or revise any forward-looking statements.
12.03.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group AG.
Language: English Company: BRAIN Biotech AG Darmstädter Straße 34-36 64673 Zwingenberg Germany Phone: +49 (0) 62 51 / 9331-0 Fax: +49 (0) 62 51 / 9331-11 E-mail: [email protected] Internet: www.brain-biotech.com ISIN: DE0005203947 WKN: 520394 Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange EQS News ID: 1857077 End of News EQS News Service
1857077 12.03.2024 CET/CEST Werbung INFLATION: WELTWEIT STEIGEN DIE PREISE Viele Anleger setzen deshalb auf den Aktiv verwalteten Global Inflation Protection Basket. Informieren Sie sich über die breit gestreute Auswahl an robusten Aktien & ETFs. Nachrichten zu BRAIN Biotech AG Analysen zu BRAIN Biotech AG Immobiliensanierung mit KI – BX Morningcall mit François Bloch & Martina Bühler von Scandens Gebäudeanalysen und Sanierungsplanung – so einfach wie noch nie. Der Klimawandel gehört zu den grössten und dringendsten Herausforderungen unserer Zeit. Martina Bühler, Head Marketing bei Scandens diskutiert mit David Kunz (COO der BX Swiss), und Investmentstratege François Bloch, wie Künstliche Intelligenz der Immobilienbranche hilft schnelle und einfache Renovierungsplanung zu ermöglichen. Neben ihrer Tätigkeit beim ETH Spin-off spielt das Thema Nachhaltigkeit auch in dem von Martina Bühler gegründeten Verein: «Greenwishing» ein grosse Rolle. 👉🏽 https://bxplus.ch/bx-musterportfolio/ Inside Trading & Investment Mini-Futures auf SMI Meistgelesene Nachrichten Börse aktuell – Live Ticker Nach US-Inflationsdaten: SMI wieder höher — DAX markiert Rekordhoch — Wall Street freundlich — Asiens Börsen mit durchwachsenem Handel – Kräftige Gewinne in Hongkong Am Schweizer Aktienmarkt zeigt sich am Dienstag etwas höher. Auch der deutsche Aktienmarkt erlebt einen freundlichen Handelstag, der DAX knackt die Rekordmarke. Die Wall Street notiert fester. An den größten Börsen in Asien lief der Handel am Dienstag durchwachsen. finanzen.net News Datum Titel
{{ARTIKEL.NEWS.HEAD.DATUM | date : “HH:mm” }}
{{ARTIKEL.NEWS.BODY.TITEL}}
This content was originally published here.
